$23,145.79 consulting Payment -- Amgen Inc to Dr. Andrew Young
Cardiologist Andrew Young Receives $23,145.79 Consulting Fee from Amgen Inc. for Trulicity
This page provides a detailed analysis of a $23,145.79 consulting payment from Amgen Inc to Dr. Andrew Young. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $23,145.79 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Amgen Inc |
| Physician | Dr. Andrew Young |
| NPI Number | 1662478490 |
| Physician Specialty | Cardiology |
| Location | Jersey City, NJ |
| Date of Payment | 2024-08-25 |
| Related Drug/Device | Trulicity |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Amgen Inc made a $23.1K consulting payment to Andrew Young, a Cardiology specialist in Jersey City, NJ. The payment was associated with Trulicity. The payment of $23,145.79 to Dr. Andrew Young for consulting services related to Trulicity is a significant amount. This payment was made by Amgen Inc., a major pharmaceutical company. The payment was for consulting services, indicating a professional engagement beyond typical speaker fees or meals.
Patient Guidance: What This Payment Means for You
This payment is for consulting services and may relate to the development or understanding of medications like Trulicity. Discuss any questions about your physician's financial relationships with drug companies with your doctor. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for specialists can vary widely, but this amount is on the higher end for a single payment, warranting further investigation into the nature of the consulting services provided.
Regulatory Context: Sunshine Act Requirements
Payments to physicians from pharmaceutical companies are subject to disclosure under the Sunshine Act, requiring transparency in financial relationships to prevent potential conflicts of interest.
Related Topics
This payment is related to the following healthcare transparency topics:
- consulting-fees
- pharmaceutical-payments
- cardiologist-payments
- amgen-inc
- trulicity
- physician-compensation
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $23.1K payment for?
This was a consulting payment of $23.1K from Amgen Inc to Andrew Young, categorized as "Consulting Fee". It was associated with Trulicity. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Andrew Young accept pharmaceutical money?
Yes, Andrew Young received this $23.1K payment from Amgen Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Andrew Young's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $23.1K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Cardiology?
To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Andrew Young's relationship with Amgen Inc?
The payment amount is substantial, suggesting a potentially in-depth consulting arrangement. This $23.1K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Cardiology?
The specific drug mentioned, Trulicity, is a GLP-1 receptor agonist used for type 2 diabetes, which is relevant to cardiology.
What should patients do after learning about this payment?
This payment is for consulting services and may relate to the development or understanding of medications like Trulicity. Discuss any questions about your physician's financial relationships with drug companies with your doctor.
What else should I know about this consulting payment?
The payment date is recent, falling within the current reporting period.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.